Summary

● The company has poor fundamentals for a short-term investment strategy.


Strengths

● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock

● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.


Weaknesses

● Stock prices approach a strong long-term resistance in weekly data at USD 115.25.

● The group shows a rather high level of debt in proportion to its EBITDA.

● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

● The company's enterprise value to sales, at 3.22 times its current sales, is high.

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.54 times its estimated earnings per share for the ongoing year.

● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

● For the past year, analysts have significantly revised downwards their profit estimates.

● Below the resistance at 115.25 USD, the stock shows a negative configuration when looking looking at the weekly chart.